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A fast screening method was developed to assess the pathogenicity of a diverse collection of environmental and clinical Burk-
holderia cepacia complex isolates in the nematode Caenorhabditis elegans. The method was validated by comparison with the stan-
dard slow-killing assay. We observed that the pathogenicity of B. cepacia complex isolates in C. elegans was strain-dependent but
species-independent. The wide range of observed pathogenic phenotypes agrees with the high degree of phenotypic variation among
species of the B. cepacia complex and suggests that the taxonomic classiﬁcation of a given strain within the complex cannot predict
pathogenicity.
 2005 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
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The genus Burkholderia comprises a diverse group of
Gram negative microorganisms that thrive in diﬀerent
ecological niches including soil, water, the rhizosphere,
and humans. In particular, the Burkholderia cepacia
complex consists of ten closely related species or genom-
ovars that can be isolated from both environmental and
clinical sources [1]. Usually non-pathogenic for healthy
individuals, B. cepacia complex isolates cause a variety
of infections in immunocompromised patients, and in0378-1097/$22.00  2005 Federation of European Microbiological Societies
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E-mail address: scardona@uwo.ca (S.T. Cardona).patients with chronic granulomatous disease (CGD)
and cystic ﬁbrosis (CF) [1]. Two species of the B. cepacia
complex, B. multivorans (formerly genomovar II) and B.
cenocepacia (formerly genomovar III), account for the
majority of isolates from CF patients in North America
[2,3] and Europe [4]. B. cepacia complex isolates diﬀer in
utilization of carbon sources, susceptibility to antibiotics
[5–7], and the presence of a pathogenicity island [8].
Also, individual diﬀerences among strains from the same
species have been detected in amoeba [9], murine [10]
and plant infection models [11].
The nematode Caenorhabditis elegans, lacking adap-
tive immunity, is a useful host model for studying innate
immune responses to bacterial pathogens [12,13]. This
model is genetically tractable from the perspectives of. Published by Elsevier B.V. All rights reserved.
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evolutionary conserved mechanisms of microbial patho-
genesis and innate immunity [14–17]. A previous study
employed a small number of the B. cepacia complex
strains and demonstrated that they can cause infection
in C. elegans [18], and the infection-like process was
characterized using the B. cenocepacia strain H111
[19]. However, a systematic analysis of the pathogenic
diversity within B. cepacia complex species has not been
performed in this model. In this study, we have devel-
oped a rapid screening method to characterize in C. ele-
gans the pathogenic phenotypes of a representative
number of environmental and clinical B. cepacia com-
plex isolates. We observed a wide range of pathogenic
phenotypes and demonstrate that the pathogenicity of
B. cepacia complex isolates in C. elegans is strain-depen-
dent but species-independent.2. Materials and methods
2.1. Bacterial and nematode strains
Caenorhabditis elegans Bristol N2 and DH26 strains
were obtained from the Caenorhabditis Genetics Center,
University of Minnesota, Minneapolis. A collection of
B. cenocepacia K56-2 transposon mutants with survival
defects in the rat lung model of infection [20] was used to
develop the 48-well plate mortality assay. A subset of
these mutants is listed in Table 1. Strains belonging to
the B. cepacia complex are listed in Table 2. All species
were represented by at least three isolates with the
exception of one single strain of B. ubonensis (genom-
ovar X). Most of the strains from the B. cepacia complex
experimental strain panel [21,22] were also included in
the study. When available, information on the geo-
graphic and biological sources of the isolates was in-
cluded in Table 2. Most isolates were obtained from
North America and Europe. A few strains were ob-
tained from Argentina, Australia, Senegal and Vietnam.
2.2. Forty-eight-well plate mortality assay
Forty-eight-well plates containing 600 ll of NG agar
[19] were inoculated with 20 ll of overnight bacterial
cultures, incubated at 37 C for 3 h, and then again
overnight at room temperature to allow the formation
of a bacterial lawn. Five to ten hypochlorite-synchro-
nized L4 larvae of C. elegans strain Bristol N2 were
deposited onto each well and incubated at 20 C. The
percentage of live worms and their morphological
appearance was registered after two days. The total
number of nematodes including the parental worms (if
still alive) and the progeny nematodes (if any) was
scored after ﬁve days. The non-pathogenic Escherichia
coli OP50 strain was used as a negative control. Frompreliminary experiments, comparing infections with
E. coli OP50 and B. cenocepacia K56-2, we established
that a given strain of the B. cepacia complex was path-
ogenic for C. elegans if one of the following criteria
was met: (i) a sick appearance at day 2, which included
reduced locomotive capacity and the presence of dis-
tended intestine; (ii) percentage of live worms at day
2 6 50%; and (iii) total number of worms at day
5 6 50. The presence of any one, two or three of these
criteria was scored as 1, 2, and 3, respectively, diﬀeren-
tiating mild from severe infections (Tables 1 and 2).
Any given strain was considered pathogenic when at
least one criterion was observed (pathogenicity score 1,
2 or 3). Conversely, a strain was considered non-patho-
genic when no symptoms of disease were observed dur-
ing the course of the infection experiment (pathogenicity
score 0).
2.3. Slow-killing assay
Slow-killing assays were performed using the C. ele-
gans strain DH26 [23]. Six-well plates containing 5 ml
of NG agar [19] were inoculated with 50 ll of the over-
night cultures adjusted to an OD600 of 1.7 and incubated
24 h at 37 C to allow the formation of a bacterial lawn.
Twenty to forty hypochlorite-synchronized L4 larvae of
C. elegans strain DH26 were inoculated to each plate
and incubated at 25 C. Each assay was performed in
triplicate. Plates were scored for live and dead worms
every 24 h. For each killing assay nematode survival
was calculated by the Kaplan–Maier method, and sur-
vival diﬀerences were tested for signiﬁcance by the use
of the log rank test (GraphPad Prism, version 4.0).3. Results and discussion
3.1. Validation of the 48-well plate mortality assay
To validate the 48-well plate mortality assay in the C.
elegans model as a rapid method for screening large
numbers of strains, we exploited our collection of trans-
poson mutants in B. cenocepacia strain K56-2, which
display reduced survival rates in the rat agar bead model
of lung infection [20]. We reasoned that these mutants
would elicit a wide range of pathogenic phenotypes in
the C. elegans model, thus, facilitating the assessment
of the pathogenicity criteria. These parameters were
based on the percent survival and appearance of worms
at two days post-infection, and the total number of
parental and progeny nematodes after ﬁve days, as de-
scribed in Section 2. As controls, we performed infec-
tions with the non-pathogenic E. coli strain OP50
(data not shown) and the parental B. cenocepacia K56-
2 whose pathogenic phenotypes were assigned scores
of 0 and 3, respectively. From the 75 mutants screened,
Table 1
Comparison between the 48-well plate mortality assay and the slow-killing assay using selected B. cenocepacia K56-2 transposon mutants
Strain Known or putative function of the mutated genea 48-Well plate mortality assay of C. elegans Bristol N2 strain Slow-killing assay of C. elegans DH26
Appearance
at day 2b
% of live
worms at day 2
Total number of
worms at day 5
PSc % of live
worms at day 2
Median survival (days)d P-valuee
4A7 paaE, ferredoxin reductase Normal 100 100–500 0 97 Undeﬁned <0.0001
3A3 Cation eﬄux pump Normal 100 50–100 0 71 3 <0.0001
10F1 Hypothetical protein Normal 90 50–100 0 73 3 <0.0001
16H8 ugpB, glycerol 3-P binding
periplasmic protein
Normal 72 50–100 0 71 3 <0.0001
28D9 Translation initiator inhibitor
tdcF and yjgF
Sick 66 50–100 1 96 3 <0.0001
36B4 cpxA, capsular polysaccharide
export ATP-binding protein
Sick 100 50–100 1 69 3 <0.0001
38E2 hemK, methyltransferase Sick 100 50–100 1 83 3 <0.0001
33H3 wbiI, epimerase/dehydratase Sick 50 20–50 2 60 3 <0.0001
34A1 Transcriptional regulator Sick 50 10–20 2 27 2 0.5059 NS
28D8 UTP-glucose-1-phosphate Sick 40 0 3 20 2 0.2162 NS
20D2 D-lactate-dehydrogenase/oxidoreductase Sick 47 0 3 34 2 0.3695 NS
K56-2 Parental strain Sick 22 0 3 24 2 –
OP50 E. coli feeding strain Normal 100 50–100 0 100 Undeﬁned <0.0001
NS, non-signiﬁcant.
a As described by Hunt et al. [20].
b The appearance of worms was scored as sick when impaired locomotion or a distended intestine was found.
c Pathogenicity score 0, no signs of disease; 1, 2 and 3, one two or three symptoms of disease, respectively (see Section 2).
d Obtained from Kaplan–Meier survival plots (see Fig. 1).
e P values calculated from pair wise comparisons (log rank test) by each transposon mutant strain versus K56-2 wild-type strain.
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Table 2
Pathogenicity of B. cepacia complex strains in C. elegans Bristol N2
Species GVa Strain Comments Appearance
at day 2
% of live
worms at day 2
Number of
worms at day 5
PSb
B. cepacia I ATCC 25416 Onion, U.S.A., Bccespc Sick 67 50–100 1
CEP0509 CF, Australia, Bccesp Normal 95 >500 0
FC124 CGD, Canada Sick 94 50–100 1
MC353 Environmental (onion) Sick 8 0 3
MC76 Environmental (onion) Sick 13 0 3
MC81 Environmental (onion) Sick 17 20–50 3
B. multivorans II 249-2 Laboratory, U.S.A., Bccesp Normal 100 50–100 0
ATCC 17616 Soil, U.S.A., Bccesp Normal 100 100–500 0
C0514 CF, sputum, Canada Normal 100 100–500 0
C3430 CF, sputum, Canada Normal 93 100–500 0
C4297 CF, sputum, Canada Sick 88 50–100 1
C5274 CF, sputum, Canada Normal 100 50–100 0
C5393 CF, Canada, Bccesp Normal 73 100–500 0
C5568 CF, sputum, Canada Sick 66 50–100 1
CEP0108 CGD, Lung, U.S.A. Normal 100 100–500 0
CEP484 CF, U.S.A. Normal 100 100–500 0
FC0147 CGD, Canada Normal 100 100–500 0
FC0442 CGD, blood, U.S.A. Normal 100 100–500 0
LMG 16660 CF, U.K., Bccesp,
Glasgow epidemic strain
Normal 100 100–500 0
LMG 16665 brain abscess, U.K. Normal 100 100–500 0
CEP1016 CF, U.K. Sick ND 0 2
CEP1017 CF, U.K. Normal 80 100–500 0
CEP1018 U.K. Normal 100 100–500 0
CEP1019 CF, Ireland Sick 88 20–50 2
B. cenocepacia III BC7 CF, Canada, Bccesp Normal 85 50–100 0
C1484 CF, Canada Sick 29 0 3
C3865 CF, Canada Sick 92 0 2
C4455 CF, Canada Sick 100 >500 1
C5424 CF, Canada, Bccesp Normal 98 100–500 0
CEP024 CF, U.S.A., Bccesp Normal 84 50–100 0
CEP0931 CGD, endotracheal tube, U.S.A. Sick 55 0 2
CEP1067 CGD, blood, Canada Sick 28 0 3
CEP511 CF, Australia, Bccesp Normal 90 100–500 0
CEP054 CF, U.S.A. Normal 100 50–100 0
CP 706-J CF, U.S.A. Sick 60 50–100 1
F28368-82 CF, Canada Sick 31 20–50 3
F38192-89 CF, Canada Sick 44 0 3
FC0127 CGD Sick 92 20–50 2
H111 CF Sick 33 0 3
J2315 CF, U.K., Bccesp Normal 97 20–50 1
K56-2 CF, Canada, Bccesp Sick 22 0 3
L10 CF, Canada Sick 57 0–10 2
PC 527-I CF, U.S.A. Sick 30 0 3
PC 701-J CF, U.S.A. Sick 78 0–10 2
B. stabilis IV C6061 CF, sputum, Canada Normal 57 50–100 0
CEP0559 CF, Canada Normal 78 50–100 0
FC0473 CF, Belgium Normal 100 50–100 0
LMG 14086 respirator, U.K., Bccesp Sick 45 10–20 3
LMG 14294 CF, Belgium, Bccesp Normal 80 100–500 0
LMG 18870 CF, Canada, Bccesp Normal 74 50–100 0
LMG 18888 Human blood, Belgium, Bccesp Sick 46 0–10 3
B. vietnamiensis V C2822 CF, sputum, Canada Normal 81 100–500 0
FC0369 Rhizosphere, Vietnam Normal 100 50–100 0
FC0441 CGD, Canada Sick 46 >500 2
CCUG 31370 CF, Sweden. Bccesp Normal 100 100–500 0
LMG18835 CF, U.S.A., Bccesp Sick 100 100–500 1
B. dolosa VI CEP021 CF, U.S.A. Normal 96 100–500 0
CFLG CF, Argentina Normal 92 50–100 0
L6 CF, Canada Sick 81 10–20 2
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Table 2 (continued)
Species GVa Strain Comments Appearance
at day 2
% of live
worms at day 2
Number of
worms at day 5
PSb
LMG 18943 CF, U.S.A. Sick 64 50–100 1
LMG 21443 Alysicarpus glumaceus,
root nodule, Senegal, Bccesp
Sick 100 0–10 2
LMG 21820 CF, U.K., Bccesp Normal 87 20–50 1
B. ambifaria VII LMG 17828 Corn roots, U.S.A., Bccesp Sick 57 0 2
LMG 19182 pea rhizosphere, U.S.A., Bccesp Sick 83 0–20 2
LMG 19467 CF, Australia, Bccesp Sick 4 0 3
B. anthina VIII LMG 16670 Carludovica palmata,
rhizosphere. U.K., Bccesp
Sick 36 0 3
LMG 20980 Soil rhizosphere, U.S.A., Bccesp Sick 100 10–20 2
LMG 20983 CF, sputum, U.K., Bccesp Sick 75 0 2
LMG 21821 CF, U.S.A., Bccesp Sick 91 0–10 2
B. pyrrocinia IX LMG 14191 Soil, Fujisawa Pharm. Co.
Bccesp, Patent strain
Sick 49 0–10 3
LMG 21822 Cornﬁeld soil, U.S.A., Bccesp Sick 28 0 3
LMG 21823 Water, U.S.A., Bccesp Sick 17 0 3
LMG 21824 CF, U.K., Bccesp Sick 40 0 3
B. ubonensis X LMG 20358 Surface soil, Thailand. Bccesp Sick 10 0 3
Comparable results were obtained in at least two independent experiments.
a Genomovar.
b Pathogenicity score as described in Section 2.
c B. cepacia complex experimental strain panel.
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parable to that of the parental K56-2 strain. This sug-
gested that the mutated genes in these strains had no
eﬀect in attenuating the infection in C. elegans. In con-
trast, 44 mutants displayed various levels of attenuation,
including 33 mutants with pathogenicity score 2, ﬁve
mutants with pathogenicity score 1, and 6 mutants with
pathogenicity score 0.
To compare the 48-well plate mortality assay with the
more established slow-killing assay, we selected a subset
of the transposon mutants with diﬀerent pathogenicity
scores (Table 1), which were employed in killing assays
using the C. elegans DH26 strain [23]. This nematode
strain has a temperature sensitive mutation in the sper-
matogenesis fer-15 gene. As worms are sterile at 25 C,
it is possible to count the original worms for longer peri-
ods of time after infection without the interference of
progeny worms. The rate of killing by B. cenocepacia
K56-2 on C. elegans DH26 at 25 C and on C. elegans
Bristol N2 at 20 C was indistinguishable (data not
shown). The B. cenocepacia K56-2 mutants examined
in C. elegans DH26 also exhibited diﬀerent degrees of
pathogenicity (Fig. 1) that generally correlated well with
the results of the 48-well plate mortality assay (Table 1).
The transposon mutants with pathogenicity scores 0 and
1 in the 48-well killing assay were highly attenuated with
respect to the K56-2 wild-type strain when tested in the
slow-killing assay (P-value < 0.0001). While the mutant
4A7 did not show any signiﬁcant nematode killing activ-
ity over a 5-day period, C. elegans infected with mutants3A3, 10F1, 16H8, 28D9, 36B4, and 38E2 displayed a
median survival of three days (Table 1). In contrast, mu-
tants 28D8 and 20D2 (pathogenicity score 3) were as
pathogenic as K56-2 (Table 1). The mutant 33H3 (path-
ogenicity score 2) showed an attenuated phenotype (P-
value < 0.0001 and median survival of three days) in
the slow-killing assay. However, the percent of live
worms at day 2 was lower than the rest of the transpo-
son mutants that also showed an attenuated phenotype
and had pathogenicity scores 0 and 1. The only excep-
tion to this correlation was the mutant 34A1, which
showed a pathogenicity score 2 in the 48-well mortality
assay but was not signiﬁcantly diﬀerent from K56-2 in
the slow-killing assay. This disparity could be due to
an overestimation in the number of counted worms at
day 2 in the 48-well plate mortality assay. Therefore,
we conclude from these observations that the 48-well
plate mortality assay correlates with the slow-killing as-
say. Further studies are underway in our laboratory to
characterize in detail the function of the mutated genes
in relation to infection in C. elegans.
3.2. Pathogenicity of clinical and environmental
B. cepacia complex strains in the C. elegans model
The pathogenicity of representative strains from theB.
cepacia complex was screened with the 48-well plate
mortality assay.B. cepacia (genomovar I)was represented
by six strains, four environmental isolates and two clinical
strains isolated from CF and CGD patients. The
Fig. 1. Kaplan–Meier survival plots of selected transposon mutants. The killing ability of wild-type B. cenocepacia K56-2 strain (n = 76) was
compared with that of the STM-mutants 4A7 (n = 109), 3A3 (n = 77), 10F1 (n = 71), 16H8 (n = 72), 28D9 (n = 87), 36B4 (n = 45), 38E2 (n = 35),
33H3 (n = 109), 34A1 (n = 110), 28D8 (n = 71) and 20D2 (n = 93) in slow-killing assay experiments using C. elegans DH26 strain. n, Number of
worms at day 0. Dashed lines with squares, B. cenocepacia K56-2 strain; solid lines with triangles, any given transposon mutant of K56-2 strain
(indicated in the title of each graphic).
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enous, ranging from the non-pathogenic CEP0509 to the
highly pathogenic strains MC353, MC76 and MC81.Fourteen of the 18 B. multivorans (genomovar II) strains
were non-pathogenic. Two isolates, C4297 and C5568
caused a mild infection in C. elegans while strains
S.T. Cardona et al. / FEMS Microbiology Letters 250 (2005) 97–104 103CEP1016 and CEP1019 were the most pathogenic. B.
cenocepacia (genomovar III) strains were highly diverse
with respect to their pathogenic phenotypes. Even the
strains K56-2, J2315 and BC7, which are considered to
be clonal [21], exhibited diﬀerent pathogenic phenotypes.
Strain K56-2 had the highest degree of pathogenicity
while J2315 only caused a slight decrease in the number
of progeny worms. This could be attributed to the diﬀer-
ences in O-antigen expression between strains K56-2 and
J2315 [24]. However, reconstitution of O-antigen produc-
tion in J2315 by complementation did not render the
strain more pathogenic in C. elegans (data not shown).
Hence, the diﬀerences between these two clonal strains
in the pathogenicity for C. elegans might be explained
by diﬀerences other than O-antigen production. Five of
the seven B. stabilis (genomovar IV) isolates were highly
attenuated, while the degree of pathogenicity of isolates
from B. vietnamiensis (genomovar V) and B. dolosa
(genomovar VI) was diverse. All isolates from B. ambifa-
ria (genomovar VII)B. anthina (genomovar VIII),B. pyr-
rocinia (genomovar IX), and B. ubonensis strain
LMG20358 were pathogenic for C. elegans. But we can-
not conclude that all the strains from these species are
pathogenic given that we only had a limited number of
strains available for this study.
The distribution of pathogenic and non-pathogenic
strains according to their genomovar classiﬁcation is
summarized in Fig. 2. On average, the proportion of
strains having a pathogenic phenotype was highest in
B. cepacia and B. cenocepacia, while B. multivorans
and B. stabilis strains were the least pathogenic (Fig.
2). Environmental isolates appeared to be more patho-genomovars
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Fig. 2. Distribution of pathogenicity of B. cepacia complex isolates in
the C. elegans Bristol N2 model. The strains shown in Table 2 were
grown in NG agar plates at 37 C and the 48-well mortality assay was
performed. Percent of pathogenic and non-pathogenic strains was
calculated for each genomovar (see Section 2). Numbers over the bars
represent the total number of isolates in each genomovar.genic for C. elegans than the clinical isolates (78% of
the environmental isolates and 52% of the human dis-
ease isolates). However, it cannot be concluded that
the clinical and environmental isolates necessarily diﬀer
in their capacity to cause disease in humans. More
likely, the observed diﬀerences may reﬂect the adapta-
tion of clinical strains to the lung environment with
the concomitant loss of other characteristics required
for colonization and infection of C. elegans.4. Conclusions
In this study, we demonstrate that B. cepacia complex
strains show a great diversity of pathogenic phenotypes
for C. elegans. This variability, which also applies to
strains within the same species, could reﬂect either loss
or acquisition of accessory genetic material, which
may provide functional diversity among individual
strains. Therefore, the assignment of an environmental
or clinical strain as a given species or genomovar does
not predict the potential risk for infection. We also iden-
tiﬁed B. cenocepacia K56-2 transposon mutants that
were non-pathogenic in both nematodes and rats. Thus,
at least some of the survival-associated properties of B.
cenocepacia are common to both nematodes and mam-
malian hosts, as it has been demonstrated for Pseudomo-
nas aeruginosa [14,25]. A detailed analysis at the
molecular level of the pathogenicity of B. cepacia com-
plex strains in C. elegans will provide additional clues
to better understand the adaptation of these microbes
to multiple environments.Acknowledgments
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